NeuroPace Revenue Jumps 22 Percent in Q2

NeuroPace (NASDAQ:NPCE) reported strong Q2 2025 results, with record GAAP revenue of $23.5 million, up 22.0% year-over-year and exceeding estimates, primarily driven by robust RNS System adoption. Gross margin significantly improved to 77.1%, leading to a raised full-year guidance of 75-76%. While operating expenses increased 22.5% due to one-time personnel costs, free cash flow improved, and the company raised its full-year revenue outlook to $94-98 million. Strategically, NeuroPace is phasing out lower-margin SEEG products to enhance profitability, though a key clinical trial (NAUTILUS) for idiopathic generalized epilepsy yielded mixed results, failing its primary effectiveness endpoint but showing positive secondary outcomes.

Analysis

NeuroPace (NPCE) delivered a strong second quarter, highlighted by record GAAP revenue of $23.5 million, a 22.0% year-over-year increase that surpassed analyst estimates. This top-line growth was driven by accelerating commercial adoption of its core RNS System, evidenced by record highs in active prescribers and treatment centers. Profitability metrics showed significant improvement, with gross margin expanding 3.7 percentage points to 77.1%, prompting management to raise its full-year gross margin guidance to a range of 75-76%. This margin strength is further supported by the strategic decision to phase out the lower-margin SEEG product line. However, the positive operational performance was tempered by a 22.5% increase in operating expenses, largely attributable to $3.5 million in one-time personnel and executive transition costs, which contributed to a GAAP EPS miss at $(0.26). Despite this, the company improved its cash management, narrowing its free cash flow loss to $(2.3) million from $(4.0) million in the prior year. A key development is the mixed outcome of the NAUTILUS clinical study, which failed its primary effectiveness endpoint but showed positive secondary data, creating uncertainty around its planned FDA submission for an expanded indication in idiopathic generalized epilepsy.

Key Decisions for Investors

• Investors should recognize the strong commercial execution and improving profitability profile, evidenced by the 22% revenue growth, upgraded full-year guidance, and strategic exit from lower-margin products.
• It is critical to monitor the outcome of the planned FDA submission for the RNS System's use in generalized epilepsy, as the NAUTILUS study's failure to meet its primary endpoint introduces a significant binary risk for future growth.
• Scrutinize operating expense trends to ensure the one-time charges do not mask underlying cost inflation and that cash burn remains manageable relative to the company's $62.1 million cash position.
• Consider the stable CMS reimbursement and planned pediatric FDA submission as potential positive catalysts that could broaden the addressable market, offsetting some of the clinical trial risks.